Antiplatelets versus anticoagulants for the treatment of cervical artery dissection: Bayesian meta-analysis

PLoS One. 2013 Sep 5;8(9):e72697. doi: 10.1371/journal.pone.0072697. eCollection 2013.

Abstract

Objective: To compare the effects of antiplatelets and anticoagulants on stroke and death in patients with acute cervical artery dissection.

Design: Systematic review with Bayesian meta-analysis.

Data sources: The reviewers searched MEDLINE and EMBASE from inception to November 2012, checked reference lists, and contacted authors.

Study selection: Studies were eligible if they were randomised, quasi-randomised or observational comparisons of antiplatelets and anticoagulants in patients with cervical artery dissection.

Data extraction: Data were extracted by one reviewer and checked by another. Bayesian techniques were used to appropriately account for studies with scarce event data and imbalances in the size of comparison groups.

Data synthesis: Thirty-seven studies (1991 patients) were included. We found no randomised trial. The primary analysis revealed a large treatment effect in favour of antiplatelets for preventing the primary composite outcome of ischaemic stroke, intracranial haemorrhage or death within the first 3 months after treatment initiation (relative risk 0.32, 95% credibility interval 0.12 to 0.63), while the degree of between-study heterogeneity was moderate (τ(2) = 0.18). In an analysis restricted to studies of higher methodological quality, the possible advantage of antiplatelets over anticoagulants was less obvious than in the main analysis (relative risk 0.73, 95% credibility interval 0.17 to 2.30).

Conclusion: In view of these results and the safety advantages, easier usage and lower cost of antiplatelets, we conclude that antiplatelets should be given precedence over anticoagulants as a first line treatment in patients with cervical artery dissection unless results of an adequately powered randomised trial suggest the opposite.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Review
  • Systematic Review

MeSH terms

  • Anticoagulants / therapeutic use*
  • Bayes Theorem
  • Carotid Artery, Internal, Dissection / drug therapy*
  • Humans
  • Odds Ratio
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Treatment Outcome
  • Vertebral Artery Dissection / drug therapy*

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors

Grants and funding

Hakan Sarikaya was supported by a research grant from Swiss National Foundation (SNF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.